Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer
W. Fraser Symmans, Angela M. DeMichele, Michael J. Campbell, Amy Wilson et al.
Citations
1 citations
Journal
Breast Cancer Research and Treatment
Topics
HER2/EGFR in Cancer Research
Field-Weighted Citation Impact (FWCI)
0.28
article
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer
W. Fraser Symmans, Angela M. DeMichele, Michael J. Campbell, Amy Wilson, Ruby Singhrao, Judy C. Boughey, Douglas Yee, Nola M. Hylton, Katherine Steeg, Julia L. Clennell, Smita Asare, Meredith Buxton, A. Jo Chien, Hyo S. Han, Christina Yau, Jeffrey B. Matthews, Claudine J. Isaacs, Jane Perlmutter, Laura J. Esserman, Donald A. Berry, Hope S. Rugo, Anne M. Wallace, Laura J. van’t Veer
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Breast Cancer Research and TreatmentVol. 209(3)
Institutions
University of Minnesota (US), The University of Texas MD Anderson Cancer Center (US), University of California, San Francisco (US), Georgetown University (US), Moffitt Cancer Center (US), University of California San Diego (US), Berry & Associates (United States) (US), Quantum Leap Healthcare Collaborative (US), Mayo Clinic in Arizona (US), Gemini Computers (United States) (US), University of San Francisco (US), University of Pennsylvania (US)
Funders
Foundation for the National Institutes of Health, Breast Cancer Research Foundation, William K. Bowes, Jr. Foundation, National Institutes of Health